Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 22

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 22
---
 |     | seek regulatory approvals for our product candidate or any future product candidates; |

| • |     | commercialize our current product candidate or any future product candidates, if approved; |

| • |     | take steps toward our goal of being an integrated biopharmaceutical company capable of supporting commercial 
 activities, including establishing sales, marketing and distribution infrastructure;                         |

| • |     | attract, hire, and retain qualified clinical, scientific, operations, and management personnel; |

| • |     | add and maintain operational, financial, and information management systems; |

| • |     | protect, maintain, enforce, and defend our rights in our intellectual property portfolio; |

| • |     | defend against third-party interference, infringement, and other intellectual property claims, if any; |

| • |     | address any competing therapies and market developments; |

| • |     | experience any delays in our preclinical studies or clinical trials and regulatory approval for our product                                               
 candidate due to macroeconomic conditions, geopolitical conflicts, or other global events, including any health epidemics and their residual effects; and |

| • |     | incur additional costs, including legal, accounting, and other expenses, associated with operating as a public 
 company following the completion of this offering.                                                             |

We have no product candidates approved for commercial sale and have not generated any revenue from the sale of products. Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue, if any, unless and until we, either alone or with a collaborator, are able to obtain regulatory approval for, and successfully commercialize, our product candidate for its initial and potential additional indications, or any other product candidates we may develop in the future. Successful commercialization will require achievement of many key milestones, including demonstrating each product candidate’s safety and efficacy in clinical trials, obtaining regulatory approval for these product candidates, manufacturing, marketing, and selling those products for which we, or any of our future collaborators, may obtain regulatory approval, satisfying any post-marketing requirements, and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent of any further losses, or if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never generate revenues that are large enough for us